<DOC>
	<DOC>NCT01833130</DOC>
	<brief_summary>This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA (BOTOX®) in adults with chronic migraine.</brief_summary>
	<brief_title>Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>History of chronic migraine for at least 6 months prior to the screening visit Fifteen or more headache days during the 4week screening period (≥4 headache episodes lasting ≥4 hours and ≥50 % of headache days are migraine) Conditions causing chronic facial pain such as Temporomandibular Disorder (TMD) and fibromyalgia Use of headache prophylaxis medication within 4 weeks of the screening visit Diagnosis of Myasthenia gravis, EatonLambert Syndrome, Amyotrophic Lateral Sclerosis Previous use of any botulinum toxin of any serotype for any reason Skin infections or acne that would interfere with the injection sites Acupuncture, transcutaneous electrical nerve stimulation (TENS), cranial traction, dental splints for headache, nociceptive trigeminal inhibition, occipital nerve block treatments, or injection of anesthetics/steroids within 4 weeks of screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>